Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04026997 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
A Phase 2 study, sponsored by CinDome Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT04026997 is a Phase 2 study that was terminated before completion, run by CinDome Pharma. The registered enrollment target is 72 participants.
The verdict
NCT04026997, a Phase 2 study, was terminated before completion, sponsored by CinDome Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.
Interventions
- DRUG Placebo
- DRUG CIN-102 Dose 1
- DRUG CIN-102 Dose 2
- DRUG CIN-102 Dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-09-11 |
| Est. Completion | 2020-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04026997
The ClinicalTrials.gov registry entry for NCT04026997 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CinDome Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04026997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04026997 about?
NCT04026997 is a clinical study titled "A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis". This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.
What is the current status of trial NCT04026997?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2019-09-11. Estimated completion is 2020-12-17.
What interventions are being tested in trial NCT04026997?
The interventions under investigation include: Placebo (DRUG), CIN-102 Dose 1 (DRUG), CIN-102 Dose 2 (DRUG), CIN-102 Dose 3 (DRUG).
Who is sponsoring clinical trial NCT04026997?
This trial is sponsored by CinDome Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.